Dustin Hammers

, PhD, ABPP(CN)

Associate Professor, Department of Neurology, Indiana University School of Medicine

Dustin Hammers is a board-certified clinical neuropsychologist and Associate Professor in the Department of Neurology at Indiana University (IU). Dr. Hammers is the lead neuropsychologist involved in the NIA-funded Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS), and he is currently the Principal Investigator on the NIA- and Alzheimer’s Association–funded study Lifestyle Interventions for the Treatment of Early-Onset AD Study (LITES). His research emphasizes the characterization of cognitive declines in Early-Onset AD, and the evaluation of diagnostic consistency between cognitive and advanced AD biomarkers (β-amyloid and tau) in an effort to improve diagnostic accuracy. Additional areas of interest include examining the assessment of cognitive change over time, teleneuropsychology and digital cognitive assessments, and the detection of early memory decline in elderly and dementia populations through computerized batteries and novel learning measures. He currently serves as Associate Editor of Alzheimer’s & Dementia: Diagnosis, Assessment, & Disease Monitoring, and has been the Guest Editor for a special issue from the Journal of Clinical and Experimental Neuropsychology. In addition to being the lead neuropsychologist for the multi-center NIA-funded Anti-NMDA Receptor Encephalitis ExTINGUISH trial, he serves on the Global CEO Initiative on Alzheimer’s Disease Work Group on appropriate use criteria for digital cognitive assessments. Finally, he is the past Chair of the American Psychological Association’s (APA) Committee on Rural Health, and is currently a Liaison for the Public Interest Advisory Committee, APA Society for Clinical Neuropsychology.

Read more

This Speaker's Sessions

PANEL
Thursday Oct. 17
-
3:30–4:20 PM ET
Watch Replay
Now Live!

Alzheimer’s Detection and Diagnosis: Embracing Innovative Technologies and Advancing Equity

Alzheimer’s and other dementias are underdiagnosed and often diagnosed late, particularly among women, Black people, and Latinos. At the same time, the latest treatments are most effective early in the course of the disease. This panel will explore how cutting-edge innovations—such as blood tests, digital cognitive assessments, and AI—can enhance detection and diagnosis rates for everyone. Key Question: How can we ensure new diagnostic and AI-based tools for Alzheimer's disease address disparities rather than widen them?

View SessionWatch Replay
PANEL
Tuesday Oct. 17
-
2:30–3:15 PM ET
Watch Replay
Now Live!

New Technologies for Early Detection and Diagnosis of Alzheimer’s

Scaling up technologies for early detection of Alzheimer’s pathology and cognitive impairment promises to transform the global response to Alzheimer’s disease. Digital biomarkers and fluid biomarkers (ranging from cerebrospinal fluid to blood) to detect the disease are advancing rapidly in clinical practice and will enable a more simple, timely, and accurate Alzheimer’s diagnosis.  Key Question: What do these tools and technologies mean for patients and their doctors?

View SessionWatch Replay